Ethoxzolamide
FDA-approved product (tablet, oral), marketed as Cardrase, Ethamide.
- Registered studies
- 0
- Lab records
- 2
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Ethoxzolamide. Its therapeutic class is shown instead.
- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
Ethoxzolamide reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.
AI-predicted activity
AI prediction · nothing measured- MRSA37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis82.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- M. tuberculosis: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ethoxzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma58.2% AI-predicted activityagainst MRSA50+ registered studies
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia58.1% AI-predicted activityagainst MRSA6 registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis58.1% AI-predicted activityagainst MRSA2 registered studies
- Gilteritinib FumarateExisting use: Acute myeloid leukemia, Myeloid leukemia, Neoplasm58.1% AI-predicted activityagainst MRSA3 registered studies
- DeslanosideExisting use: Cardiovascular disease58.0% AI-predicted activityagainst MRSANo documented evidence found
- CeritinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma57.8% AI-predicted activityagainst MRSA50+ registered studies
- DocetaxelExisting use: Adenocarcinoma, Breast cancer, Breast carcinoma and 19 more57.8% AI-predicted activityagainst MRSA50+ registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more57.7% AI-predicted activityagainst MRSA50+ registered studies
- IrbesartanExisting use: Cardiovascular disease, Chronic kidney disease, Chronic renal failure syndrome and 3 more57.6% AI-predicted activityagainst MRSA50+ registered studies
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more57.6% AI-predicted activityagainst MRSA50+ registered studies
- Ingenol MebutateExisting use: Actinic keratosis57.6% AI-predicted activityagainst MRSA50+ registered studies
- DigitoxinExisting use: Cardiovascular disease57.5% AI-predicted activityagainst MRSA3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.